Building 4
Room 302, 3rd Floor No.590 Ruiqing Road East Zhangjiang Hi-Tech Park, Pudong New Area
Shanghai
China
86 21 6879 8511
https://www.bio-heart.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 32
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Li Wang | Executive Chairman of the Board, CEO & GM | 761,49k | N/A | 1968 |
Mr. Yunqing Wang | CFO, Joint Company Secretary & Executive Director | 1,26M | N/A | 1985 |
Ms. Peili Wang | Financial Manager & Executive Director | 812,03k | N/A | 1984 |
Dr. Bradley Stewart Hubbard D.V.M., DVM | Chief Medical Officer | N/A | N/A | 1959 |
Ms. Siu Ying Kwok | Joint Company Secretary | N/A | N/A | 1985 |
Mr. Tao Cai | Chairperson of the Board of Supervisors & Head of Technology of BRS | 174,24k | N/A | 1987 |
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. It develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
El ISS Governance QualityScore de Shanghai Bio-heart Biological Technology Co., Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.